Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Iain R. Konigsberg has a total of 380 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Genetics in Context: Social Factors Modify Polygenic Risk Across Multiple Cardiometabolic Diseases

    by Micah R. Hysong, Sarah Hsu, Farida Akhtari, Miriam S. Udler, Josep M. Mercader, Alisa K. Manning, Michael D. Green, Iain R. Konigsberg, Luciana B. Vargas, Leslie Lange, et al.

    Polygenic risk scores (PRS) are increasingly used for disease prediction, but whether their associations vary across social contexts remains poorly understood. Here, we leveraged the large and diverse All of Us cohort to examine interactions between PRS and social determinants of health (SDoH) across eight prevalent chronic diseases and developed disease-specific polysocial risk scores (PsRS). We found consistent evidence of SDoH modification of PRS– disease associations for cardiometabolic diseases, including type 2 diabetes, coronary heart disease and chronic kidney disease, with PRS associations attenuated among more socially vulnerable populations. Joint modeling of PsRS and PRS significantly improved case status prediction across all eight diseases and PsRS were predictive for most diseases in external cohorts. These findings demonstrate that social context modifies associations between genetic risk and disease and suggest that integrating genetic and social information can refine disease prediction across diverse populations. Teaser: Both genetics and the environment influence chronic disease, but whether and how they interact remains understudied. We find evidence of genetic effect modification of polygenic risk scores (PRS) by social factors for multiple cardiometabolic traits and that jointly modeling social risk improves disease prediction across a range of chronic diseases.

  • Open Access

    Omic risk scores are associated with COPD-related traits across three cohorts

    by Iain R. Konigsberg, Luciana B. Vargas, Katherine A. Pratte, Daniel E. Guzman, Tess D. Pottinger, Kristina L. Buschur, Thomas W. Blackwell, Yongmei Liu, Kent D. Taylor, W. Craig Johnson, et al.

  • Open Access

    MT-LLE: Multi-task locally linear embedding for interpretable disease modeling from longitudinal omics data

    by Sundous Hussein, Iain R. Konigsberg, Katerina J. Kechris, Russell P. Bowler, Farnoush Banaei-Kashani

    Constructing interpretable disease models from longitudinal omics data is a central challenge in precision medicine. The goal is a low-dimensional representation in which a patient’s position encodes their molecular state and clinical severity, and along which disease progression can be read directly. Existing dimensionality reduction methods (e.g., UMAP, Variational Autoencoders) fall short of this goal: they optimize a single generic objective and are blind to clinical labels and to the temporal ordering of measurements. Consequently, trajectory inference is typically applied after the fact to an embedding that was never optimized to reveal progression, decoupling the representation from disease dynamics. Manifold learning offers a natural route to such representations, and we build on Locally Linear Embedding (LLE) to preserve the local geometry of the omics data (i.e., keeping molecularly similar patients close together in the low-dimensional space). Geometry alone, however, yields a space that is faithful to molecular similarity yet uninformative about clinical severity and progression. We therefore recast the problem as multi-task learning: MT-LLE jointly optimizes five objectives: geometric reconstruction, supervised organization by clinical stage, embedding and phenotype forecasting, and clustering. Because naively combining such heterogeneous objectives induces gradient conflicts that distort the molecular geometry, an embedded reinforcement learning agent dynamically schedules their weights during training, establishing global geometry before refining clinical boundaries. Across two independent Chronic Obstructive Pulmonary Disease (COPD) cohorts (SPIROMICS and COPDGene), MT-LLE deliberately relaxes exact geometric reconstruction, by a modest margin, in exchange for substantial gains in clinical structure. On held-out patients, a linear model reads disease severity (GOLD stage, 0–4) from the MT-LLE embedding 35–40% more accurately than from standard dimensionality reduction (0.53 vs. 0.38 F1-Macro). The gap is starker for progression: forecasting a patient’s next-visit severity from their trajectory reaches 0.38 F1-Macro, while unsupervised baselines sit near zero (0.06–0.09 F1-Macro), a temporal signal those methods fail to capture. To test whether the reinforcement learning agent earns its place, we compared it against a fixed schedule that imposes the same ordering of objectives but cannot adapt during training; the learned agent outperforms it by 13–20% across clinical metrics, showing the gains come from adapting the weights to how training unfolds, not merely from ordering the objectives correctly, and at no cost to geometric fidelity. Beyond these quantitative gains, the manifold supports complementary analyses that surface structure invisible to standard staging: static phenotyping isolates subjects with active molecular pathology despite preserved lung function; trajectory inference maps two mechanistically distinct progression axes (inflammatory fibrosis and pan-immune activation); and kinematic analysis of each patient’s speed and acceleration identifies subjects whose molecular trajectories accelerate ahead of detectable spirometric decline.

  • Open Access

    Development of a clinical prediction model using integrated epigenetics to predict COVID-19 severity

    by Cosby G. Arnold, James F. Holmes, Janine M. LaSalle, Daniel J. Tancredi, Iain R. Konigsberg, Ivana V. Yang, Michelle Edelmann, Monica Campbell, Kathleen C. Barnes, Andrew A. Monte

    Background: Epigenetic markers, including DNA methylation (DNAm), can improve early disease diagnosis and risk stratification. The objective of this study was to evaluate whether the inclusion of a DNAm score would improve performance of a clinical prediction model for COVID-19 clinical severity. Methods: We performed a retrospective cohort study of adults (>18 years) with COVID-19 who presented to the emergency department from March to June 2020, the initial peak of the COVID-19 epidemic. DNAm scores were performed on a subset of the cohort based upon availability of blood specimens, to characterize epigenetic signatures. Clinical data were obtained from an electronic data warehouse that includes clinical and biological variables. The primary outcome was a modified WHO (mWHO) ordinal score for COVID-19 clinical improvement, which stratifies severity based on respiratory support required. We performed univariate and bivariate analyses to further select variables for inclusion (p<0.05). We used ordinal logistic regression to develop a model predicting mWHO score. DNAm scores were measured at presentation using modified Infinium MethylationEPIC Arrays with 7,831 additional probes targeting 262 immune-enriched genes. We assessed the DNAm score’s incremental impact on predictive model performance, using the estimated logit-hat for the model derived for the entire cohort as an independent variable in a pair of models fit to the DNAm subsample; one with and the other without the score as a variable. The Wald test was used to quantify the incremental predictive value of the DNAm score. Discriminative capacity was quantified and compared using the c-statistic transformation of Somers D. Results: A total of 1400 patients were included, 123 with DNAm scores. DNAm score had an adjusted odds ratio of 7.13 (95% CI 1.55-32.85; p=0.01). In comparing models with and without DNAm score, the c-statistic was 0.88 (95% CI 0.82-0.93; p<0.0001) without and 0.90 (95% CI 0.85-0.95; p<0.0001) with the DNAm score, an estimated difference in c-statistic of 0.02 (p=0.14). Conclusion: The addition of DNAm scores at presentation improved prediction but not model discrimination in this small sample.

  • Open Access

    Multi-omic modelling of body mass index response to a dietary weight loss intervention

    by Emily N. Yeo, Ashley W. Scadden, Zachary T. Caterer, Kristen J. Sutton, Iain R. Konigsberg, Joanne B. Cole, Elizabeth M. Litkowski, Zhaoxing Pan, Catherine A. Lozupone, Danielle M. Ostendorf, et al.

    Obesity is a rising global health concern, with individual responses to behavioral weight loss efforts varying widely across individuals, 1 primarily due to complex physiological, psychological, an...


  • Open Access

    Multi-trait polygenic scores for COPD and COPD exacerbations implicate druggable proteins

    by Chengyue Zhang, Iain R. Konigsberg, Yixuan He, Jingzhou Zhang, Tinashe Chikowore, William B. Feldman, Xiaowei Hu, Yi Ding, Bogdan Pasaniuc, Diana Chang, et al.

    BACKGROUND: We constructed multi-trait polygenic risk scores (PRSs) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validated their performance in diverse cohorts, and identified PRS-related proteins for potential therapeutic targeting. METHODS: PRSmix + , a multi-trait PRS framework, is used to train a composite PRS (PRS multi ) in COPDGene non-Hispanic White participants ( n = 6,647). Associations of PRS multi with COPD status (GOLD 2–4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American ( n = 2,466), ECLIPSE ( n = 1,858), Mass General Brigham Biobank ( n = 15,152), and All of Us ( n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRS multi and were validated with proteomic data in COPDGene ( n = 5,173) and UK Biobank ( n = 5,012). RESULTS: PRSmix + selected 7 traits for PRS multi . In multivariable models, PRS multi was associated with COPD status (meta-analysis random effects [RE] OR 1.58 [95% CI: 1.28–1.94]) and exacerbation frequency (meta-analysis RE β 0.21 [95% CI: 0.11–0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRS multi outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRSs that were also validated with measured protein levels in COPDGene and UK Biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include RAGE/sRAGE, IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. CONCLUSIONS: Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. TRIAL REGISTRATION: COPDGene: ClinicalTrials.gov NCT00608764; ECLIPSE: ClinicalTrials.gov NCT00292552.


  • Race, Environmental Exposures, and Interstitial Lung Abnormalities

    by Ann-Marcia C. Tukpah, Jonathan A. Rose, Matthew R. Moll, Iain R. Konigsberg, Luciana B. Vargas, Claire C. Cutting, Dawn DeMeo, David A. Lynch, Edwin K. Silverman, Michael H. Cho, et al.

  • Open Access

    Quantifying Social Determinants of Health for Disease Prediction: A Multi-Level Approach Using Healthy People 2030 and All of Us Data

    by Micah R. Hysong, Alisa K. Manning, Michael Green, Iain R. Konigsberg, Luciana B. Vargas, Jayati Sharma, Leslie Lange, Megan K. Shuey, LaShaunta M. Glover, Genevieve L. Wojcik, et al.

    Despite the growing recognition that social determinants of health (SDoH) play a prominent role in shaping health outcomes, inconsistent measures across health systems and research studies - and the absence of best practices for harmonizing, transforming, or combining variables - limits our ability to incorporate them into disease models. To address this gap, we applied the Healthy People 2030 (HP2030) framework to define, quantify, and incorporate SDoH into composite scores for disease prediction modeling, using individual-level surveys and area-level socioeconomic status (SES) measures from the American Community Survey in participants from the All of Us Research Program. We compared individual and area-level metrics of different complexity and composition and assessed associations between these SDoH metrics and nine chronic conditions, including asthma, diabetes, and prostate cancer. We further compared their predictive utility to that of commonly used metrics such as SES, area-level measures (such as a deprivation index), and self-identified race and ethnicity (SIRE). We find that diseases have distinct “social architectures,” with variation in the predictive strength of SDoH and the relative contributions of individual-versus area-level factors, prompting the development of disease-specific polysocial risk scores (PsRS). Many PsRS showed improved performance when both individual- and area-level data were included, with combined models often matching or outperforming models using SIRE alone. Lastly, we performed a Phenome-Wide Association Study, suggesting that the inclusion of SDoH in disease modeling could improve the prediction of ∼70% of examined phenotypes. Our findings highlight the value of incorporating SDoH into disease prediction models and position these measures as a more interpretable, actionable alternative to race and ethnicity.


  • Open Access

    Multi-Trait Polygenic Scores for COPD and COPD Exacerbations Implicate Druggable Proteins

    by Chengyue Zhang, Iain R. Konigsberg, Yixuan He, Jingzhou Zhang, Tinashe Chikowore, William B. Feldman, Xiaowei Hu, Yi Ding, Bogdan Pasaniuc, Diana Chang, et al.

    Objectives.: To construct multi-trait polygenic scores (PRS) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validate their performance in diverse cohorts, and identify PRS-related proteins for potential therapeutic targeting. Design: Prospective cohort studies. Setting.: Genetic Epidemiology of COPD (COPDGene; 2007-present), Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE; 2005-2008), Mass General Brigham Biobank (MGBB; 2010-present), All of Us (2016-present), and UK Biobank (UKB; 2006-present). Participants.: 6,647 non-Hispanic White (NHW) and 2,466 African American (AA) participants from COPDGene; 1,858 participants from ECLIPSE; 118,566 from All of Us; 15,142 from MGBB with genetic data. 5,173 COPDGene and 5,012 UKB participants with proteomic data. Main outcome measures.: COPD status (GOLD 2-4 vs. GOLD 0) and COPD exacerbation frequency. Results.: PRSmix+, a multi-trait PRS framework, selected 7 traits for a composite PRS (PRS multi ). In multivariable models, PRS multi was associated with COPD status (meta-analysis random effects (RE) OR 1.58 [95% CI: 1.28-1.94]) and exacerbation frequency (meta-analysis RE beta 0.21 [95% CI: 0.11-0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRS multi outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRS that were also validated with measured protein levels in COPDGene and UK biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include AGER (RAGE), IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. Conclusions.: Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. Trial registration.: COPDGene: NCT00608764 ; ECLIPSE: NCT00292552 .